Fragile X syndrome arises from a CGG trinucleotide repeat expansion in the FMR1 gene, which encodes the fragile X mental retardation 1 protein (FMRP). Individuals with 5 to 44 CGG repeats at this locus carry a normal allele. Premutation alleles, defined by 55 to 200 repeats, are associated with intergenerational repeat instability but do not produce full fragile X syndrome; premutation carriers may face distinct risk for fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency. Full mutation alleles, exceeding 200 repeats, lead to hypermethylation and transcriptional silencing of FMR1, abolishing FMRP production. FMRP participates in synaptic protein synthesis regulation; its absence disrupts normal neuronal development and underlies the neurodevelopmental features of the syndrome. The condition follows an X-linked inheritance pattern. Premutation carrier frequency is estimated at approximately 1 in 250 females and 1 in 800 males in the general population.

Diagnosis of fragile X syndrome is established through molecular genetic testing using FMR1 CGG repeat analysis, employing polymerase chain reaction and Southern blot methods to determine repeat number and methylation status. Methylation analysis is incorporated because the degree of FMR1 promoter methylation correlates with gene silencing and the severity of phenotypic expression. Clinical evaluation for characteristic features—including intellectual disability or developmental delay, behavioral features, and facial morphology—guides initial recognition of the condition. Per clinical review, the diagnostic evaluation is relevant in males with unexplained intellectual disability and autism spectrum features, as well as in females with unexplained intellectual disability accompanied by pertinent family history or premature ovarian failure. Differential diagnosis encompasses other genetic causes of intellectual disability and autism spectrum features. Carrier status identification carries implications for family members given the X-linked inheritance pattern and known instability of premutation alleles across generations.

No FDA-approved disease-specific treatments for fragile X syndrome are currently available; management is supportive and symptom-based. Per clinical review, no specific targeted treatment exists, and care draws on early intervention programs and special education services as central components of management for affected children. Speech and language therapy, occupational therapy addressing sensory integration, and behavioral therapy targeting anxiety and behavioral challenges are established supportive interventions. Pharmacological management of attention, anxiety, and behavioral manifestations employs agents that are not specifically approved for fragile X syndrome. Numerous agents hold orphan drug designations for fragile X syndrome—spanning receptor-selective modulators, antioxidant compounds, and other investigational agents—but these designations do not confer FDA approval, and these agents are not currently authorized for clinical use. Per clinical review, multiple ongoing trials are evaluating pharmacological approaches targeting the neurobiological mechanisms of the condition, including synaptic function pathways and behavioral outcomes.

Fragile X syndrome is a lifelong condition with a neurodevelopmental profile that is established in early childhood. The degree of intellectual disability—typically moderate in males and generally milder in females—shapes functional capacity across the lifespan. Per clinical review, affected individuals may achieve meaningful gains in adaptive functioning and communication through sustained early intervention and educational support. Behavioral features including anxiety and repetitive behaviors may persist throughout life. Longevity is not typically severely impaired by the condition itself; quality of life and functional independence vary across individuals based on the severity of intellectual disability and the presence of behavioral or medical comorbidities. Individuals carrying the premutation face distinct risks for later-onset fragile X-associated conditions—including tremor, ataxia, and ovarian insufficiency—which carry separate natural histories from fragile X syndrome itself and are not predictive of the core syndrome's course.

Fragile X syndrome is the subject of a broad clinical and translational research effort. Numerous registered trials are investigating treatments addressing core neurodevelopmental features of the condition, including pharmacological agents targeting underlying neurobiological mechanisms, anxiety management in pediatric populations, and biomarker-based outcome assessment. Published research activity in this area encompasses over 400 classified publications across basic science, preclinical investigation, biomarker development, and clinical trial reporting. Active research directions include receptor-pathway modulation, gene reactivation strategies aimed at restoring FMR1 expression, and behavioral intervention studies. Gene therapy and biomarker publication activity have been documented within this research landscape. The FRAXA Research Foundation and the Fragile X Clinical and Research Consortium maintain infrastructure supporting clinical investigation and therapeutic development in this area.